At present, liver transplantation remains the only curative option for the patients with cirrhosis and end-stage liver diseases. The survival rate and recurrent diseases remain the major issues in the patient post-transplantation. Unani medicine is one of the oldest traditional systems of medicine which has been treating chronic liver diseases and cirrhosis (Talayyaful-Kabid) for centuries. The current study aimed to assess the impact of Unani treatment on decompensated cirrhosis and collect data to warrant further clinical trials. Authors conducted a case series on five patients with decompensated cirrhosis and portal hypertension. The disease was confirmed through FibroScan and ultrasound and treated with Unani treatment orally for seven months. Results were evaluated based on FibroScan, liver function test (LFT), EuroQol-5D (EQ5D), Child-Pugh and TTO-TIME (trade-off question). Significant improvements in LFT, fibrosis and quality of life were achieved in the studied patients. The literature related to the herbal constituents of chief medicines used to treat in this case was reviewed. The herbs proved their potential anti-oxidative, anti-inflammatory, hepatoprotective, immuno-modulator and antiviral activities, suggesting plausible mechanisms of action in the cases. The preliminary findings indicated the potential therapeutic role of Unani treatment in decompensated cirrhosis. Clinical trials should be conducted to explore further therapeutic potential of Unani treatment in decompensated cirrhosis.
Introduction
Cirrhosis is defined as the histological development of regenerative nodules surrounded by fibrous bands in response to chronic persistent liver injury, which leads to portal hypertension, ascites and end-stage liver disease. Liver fibrosis is a dynamic process resulted from the perpetuation of the normal wound healing response resulting in an abnormal continuation of fibrogenesis (connective tissue production and deposition) (1, 2) . Progression of fibrosis occurs at variable rates, depending on the cause of liver disease, environmental and host factors (1) . The major clinical consequences of cirrhosis are impaired hepatocyte (liver) function, an increased intrahepatic resistance (portal hypertension), ascites and the development of hepatocellular carcinoma (HCC) (1) (2) (3) .
Alcoholic liver disease and hepatitis C are the most common etiologies of liver fibrosis in the Western world, while hepatitis B prevails in most parts of Asia and subSaharan Africa (1) . Alcohol consumption is estimated to cause 20% -50% of liver cirrhosis (4) . After the identification of the hepatitis C virus in 1989 and of non-alcoholic steato-hepatitis (NASH) in cases with obesity and diabetes, the diagnosis of cirrhosis without an apparent cause (cryptogenic cirrhosis) is rarely made. Epidemiological studies identified regular (moderate) alcohol consumption, age above 50 years and male gender as risk factors in chronic hepatitis C, or older age obesity, insulin resistance/type 2 diabetes, hypertension and hyperlipidemia (all features of the metabolic syndrome) in NASH. Approximately 10% -20% of patients with chronic hepatitis B virus or hepatitis C virus infection have cirrhosis at first clinical presentation, and as many as 20% -30% of those who do not have cirrhosis will eventually develop this condition and its complications within one or more decades (3) .
Liver cirrhosis is a significant cause of global health burden, with more than one million deaths in 2010. Mortality from liver cirrhosis was also comparatively high in countries of Central Asia, particularly Mongolia, Uzbekistan and Kyrgyzstan, and in parts of sub-Saharan Africa (5) .
The physicians of Unani system of medicine treat liver cirrhosis and its consequences for centuries. The entity "Warm-e-Jigar Barid Saudawi" / "Taleef-ul-Kabid" in Unani literature, mimic liver cirrhosis and associated constellation of symptoms. A large number of single and compound drug preparation are documented to treat "Taleef-ul-Kabid". These scientific studies validated the antioxidant, anti-inflammatory, antiviral, immuno-modulatory and hepatoprotective nature of plant-based medicines and their bioactive principle is isolated and characterized. The cases treated in the present series include only the ones advised for liver transplantation. Due to non-availability of donor and certain factors such as restricted and costlier resources in overpopulated India, Unani treatment is given in these such as per Unani paradigms documented in Unani literature for liver cirrhosis. Unani treatment, given in this case series included multiple poly-herbal or compound preparation of Unani medicine. Therefore, the present case series was performed, primarily to explore the antifibrotic and liver regenerating effect of Unani treatment in the five cases of liver cirrhosis.
Case Presentation

Consent
Informed consent was taken from the patients. The human data included in this case series were obtained in compliance with the Declaration of Helsinki.
Outcome Measures
Results were evaluated based on the clinical manifestations and investigations such as FibroScan, liver function test (LFT) and ultrasonography of abdomen. Assessment of quality of life was also done using EuroQol-5D (EQ5D), Child-Pugh score and TTO-TIME [trade-off question] section 37 of physical health version 2, October 2005, before and after Unani treatment.
Case 1: S.J, 40-year-old non-smoker non-vegetarian Indian male admitted to the in-patient department of Majeedia Unani hospital (MUH) on 13 February 2015 with chief complains of fever, dark yellow coloration of urine, pain in abdomen, constipation, distension of abdomen, loss of appetite and general weakness for one and a half months. 2) A mixture of aqueous extracts of black nightshade (Solanum nigrum) 50 mL + chicory (Cichorium intybus) 50 mL + yarrow (Achillea millefolium) 50 mL, twice daily, 2) A mixture of aqueous extract of black nightshade (Solanum nigrum) 50 mL + aqueous extract of chicory (Cichorium intybus) 50 mL + aqueous extract of yarrow (Achillea millefolium) 50 mL, twice daily,
3) "Majoon Dabeed-ul-ward", 10 g twice daily, 4) "Habbe Kabid Naushadri", three tablets three times daily after meal.
Before starting the treatment, LFT showed serum bilirubin total, SGPT and alkaline phosphatase of 8. Haemogram and KFT were normal before and after the treatment. Before starting the treatment, the values of EQ5D, Child-Pugh and TTO score were 25%, 9 and 17, respectively, which reduced to 1%, 5 and 2, respectively, after six weeks of Unani treatment.
Case 4: AQL, a 50 year-old non-smoker non-vegetarian Indian male with diabetes referred to OPD of MUH for Unani treatment on October 17, 2014 with complains of: loss of appetite; distension of abdomen; heaviness in epigastrium; flatulence for two years. He was already treated in two major tertiary care centers in New Delhi but got no relief in his condition. After excluding viral, autoimmune and other etiologies, he was diagnosed and treated as a case of non-alcoholic fatty liver disease (NAFLD) related cirrhosis of liver with portal hypertension (HTN) with splenomegaly. Patient was allowed to continue the same oral hypoglycemic. The following regimen was advised to this patient: 1) Jigreena, two capsules, twice daily, 2) Triphala Amaltas Ras syrup, 30 mL, twice daily, 3) A mixture of aqueous extract of black nightshade (Solanum nigrum) 50 mL + aqueous extract of chicory (Cichorium intybus) 50 mL + aqueous extract of yarrow (Achillea millefolium) 50 mL, twice daily, 4) Habbe Kabid Naushadri, three tablets twice daily after meal.
Before the treatment, serum bilirubin total, SGPT, and alkaline phosphatase were 0. 1) Jigreena, 20 mL, twice daily, 2) A mixture of aqueous extract of black nightshade (Solanum nigrum) 50 mL + aqueous extract of chicory (Cichorium intybus) 50 mL + aqueous extract of yarrow (Achillea millefolium) 50 mL, twice daily, 3) Majoon Dabeed-ul-ward, two capsules, twice daily, 4) Habbe halteet, three tablets, three times daily after meal, 5) Aqueous extract of woodworm (Atremisia absinthium) 10 mL, twice daily.
Serum bilirubin, SGPT, and alkaline phosphatase were 2.3 mg/dL, 88 IU/L, and 319 IU/L respectively on 3 April 2014 which reduced to 1.0 mg/ dL, 30 IU/ mL and 151 IU/ mL, respectively, on 23 September 2015. Ultrasonography of abdomen showed mild enlarged liver with coarse echo texture, splenomegaly, and PHTN before the treatment. After treatment, the liver size was normalized with the presence of coarse echo texture, splenomegaly and PHTN. FibroScan showed reduction in liver fibrosis from 'E' median 21.1 kPa and 'CAP' median 302 dB/m to 'E' median 14.4 kPa and 'CAP' median 201 dB/m, repeated on 10 May 2014 after 20 weeks of the above mentioned Unani treatment. The values of EQ5D, Child-Pugh and TTO score were 60%, 6 and 20, respectively, which reduced to 0, 5 and 2, respectively, after 12 weeks after Unani treatment. Table 1 provides a summary of the relevant biomarkers and Table 2 provides summary of quality of life assessment in these five cases.
Discussion
The ultimate therapy for cirrhosis and end stage liver disease is liver transplantation. The major issues that remain in the care of the patient post liver transplantation are recurrent disease in the transplant, particularly HCV, and long term consequences of immunosuppressive agents such as hypertension, hyperlipidemia and renal disease (1) . Even in the developed world, although the organ donors are available, the condition of the potential recipients limit the applicability of this transplantation, and thus validation of traditional therapies to halt or reverse fibrosis are urgently needed.
In the current series, treatment was given with a decoction, including plants such as earth smoke (Fumaria officinalis), wasteland weed (Tephrosia purpurea), chirata (Swertia chiraita), East Indian globe thistle (Sphaeranthus indicus), henna (Lawsonia inermis), Indian globe thistle (Echinops echinatus), Indian ebony (Diospyros ebenum), rose flower (Rosa damsecenes), chicory seed (Cichorium intybus), yarrow seed (Achillea millefolium)and red sandalwood (Pterocarpus santalinus) or Jigreen along with aqueous extract of black nightshade (Solanum nigrum), aqueous extract of chicory (Cichorium intybus) and aqueous extract of yarrow (Achillea millefolium) and Jigreena capsules used in single and poly-herbal form for chronic liver diseases for decades in Unani system of medicine.
The immune system (both the innate and the adaptive immune cells) plays an important role in fibrosis, since persistent inflammation almost always accompanies fibrosis. In the current cases, reduction in fibrosis could be due to immuno-modulatory effect of the constituents in the above mentioned Unani treatment, proven in various animal models (6) (7) (8) .
Chronic inflammation almost always precedes and accompanies fibrotic changes and the medicines that target the inflammatory cascade typically have antifibrotic activity. Moreover, the vicious cycle of scar formation is initiated by oxidative stress so targeting ROS generation also reduces the inflammatory response, which will attenuate hematopoietic stem cell activity (HSC) and fibrogenesis.
Antioxidants can attenuate reactive oxygen species (ROS) effects and hold promise as potential antifibrotic therapies, provided that sufficient antioxidant activity can be delivered to the sites of injury within the liver.
Antioxidants exert a preventive effect on hepatocyte injury but may also be directly antifibrogenic (9) . Based on this principle, various constituents of given Unani treatment such as earth smoke (Fumaria officinalis), East Indian globe thistle (Tephrosia purpurea), chirata (Swertia chiraita), Indian globe thistle (Sphaeranthus indicus), red sandalwood (Pterocarpus santalinus), black nightshade (Solanum nigrum), chicory (Cichorium intybus) proved as potent antioxidant (inhibiting ROS generation), could be the plausible mechanism of reduction of fibrosis in FibroScan and liver regenerative effect (10) (11) (12) (13) (14) (15) . Moreover, these drugs proved helpful for their hepatoprotective and anti-inflammatory activity (15) (16) (17) (18) (19) and persistent inflammation that almost always precedes and accompanies fibrosis. Therefore, medicines that target the inflammatory cascade and mitigate further liver injury (hepatoprotective) are typically designated to possess antifibrotic activity and highlight the anti-fibrotic effect of Unani treatment (9) . Return of liver function test toward normal and reduction in inflammation could be due to hepato-protective and antiinflammatory effect of Unani treatment (9) . HBV DNA became undetectable in cases 2 and 3, could be due to antihepatitis B and antiviral properties of constituents such as Swertia chiraita (15, 20) etc.
Jigreen, for its effects on anorexia, pain in abdomen, nausea and vomiting, is probably the cause for symptomatic relief in the current cases. Jigreen also reduced bilirubin levels and improved other liver biochemical markers (21, 22) . Chicory exhibited analgesic activity in mice in hot plate and tail-flick tests (22, 23) . Majoon Dabeed-ul-ward is a compound formulation of Unani medicine, which contain Rosa damescene (Rose) as main drug, proven as hepatoprotective in various studies (15, 24) .
Conclusion
The current case series provide a novel direction in which the above mentioned Unani treatment can be used to regenerate liver and halting progression of fibrosis in cirrhosis and alleviate constellation of symptoms. Unani treatment also improved quality of life in these five cases. Therefore further studies should be performed to warrant the anti-fibrotic and regenerative effect along with elucidation of mechanism of action of Unani treatment in cirrhosis of liver.
